Last update 01 Nov 2024
Sinopharm Wuhan ZhongLian SiYao Pharmaceutical Co., Ltd.

Sinopharm Wuhan ZhongLian SiYao Pharmaceutical Co., Ltd.

Private Company|
2002|
Hubei Sheng, China
|
www.whzlsy.com

Overview

Tags

Urogenital Diseases
Cardiovascular Diseases
Nervous System Diseases
Small molecule drug

Disease domain score
A glimpse into the focused therapeutic areas
Technology Platform
Most used technologies in drug development
Targets
Most frequently developed targets
Disease DomainCount
Endocrinology and Metabolic Disease1
Infectious Diseases1
Immune System Diseases1
Nervous System Diseases1
Top 5 Drug TypeCount
Small molecule drug3
Top 5 TargetCount
MR(Mineralocorticoid receptor)1
50S subunit(50S ribosomal subunit)1
ENT(SLC29 family)1

Related

3
Drugs associated with Sinopharm Wuhan ZhongLian SiYao Pharmaceutical Co., Ltd.
Dilazep Hydrochloride Hydrate
Target
ENT
Mechanism
ENT inhibitors
Active Org.
Sinopharm Wuhan ZhongLian SiYao Pharmaceutical Co., Ltd.Sinopharm Wuhan ZhongLian SiYao Pharmaceutical Co., Ltd. [+1]
Originator Org.
Kowa Co., Ltd.Kowa Co., Ltd.
Active Indication
Glomerulonephritis, IGA [+1]
Inactive Indication-
Drug Highest PhaseApproved
First Approval Ctry. / Loc.
JP
First Approval Date18 May 1978
Acetylspiramycin
Target
50S subunit
Mechanism
50S subunit inhibitors
Active Org.
Sinopharm Wuhan ZhongLian SiYao Pharmaceutical Co., Ltd.Sinopharm Wuhan ZhongLian SiYao Pharmaceutical Co., Ltd. [+1]
Originator Org.
Aspen Pharmacare Holdings Ltd.
Active Indication
Bacterial Infections
Inactive Indication-
Drug Highest PhaseApproved
First Approval Ctry. / Loc.
JP
First Approval Date01 Sep 1967
Spironolactone
Target
MR
Mechanism
MR antagonists
Active Org.
Pfizer Japan, Inc.Pfizer Japan, Inc. [+4]
Originator Org.
G.D. Searle & Co., Inc.
Active Indication
Myocardial Infarction [+10]
Inactive Indication-
Drug Highest PhaseApproved
First Approval Ctry. / Loc.-
First Approval Date01 Jan 1959
100 Clinical Results associated with Sinopharm Wuhan ZhongLian SiYao Pharmaceutical Co., Ltd.
Login to view more data
0 Patents (Medical) associated with Sinopharm Wuhan ZhongLian SiYao Pharmaceutical Co., Ltd.
Login to view more data
100 Deals associated with Sinopharm Wuhan ZhongLian SiYao Pharmaceutical Co., Ltd.
Login to view more data
100 Translational Medicine associated with Sinopharm Wuhan ZhongLian SiYao Pharmaceutical Co., Ltd.
Login to view more data

Corporation Tree

Boost your research with our corporation tree data.
login
or
view full example data
Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 25 Dec 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Approved
3
Login to view more data

Current Projects

Drug(Targets)IndicationsGlobal Highest Phase
Spironolactone
 ( MR )		Hypokalemia
More
Approved
Dilazep Hydrochloride Hydrate
 ( ENT )		Myocardial Ischemia
More
Approved
Acetylspiramycin
 ( 50S subunit )		Bacterial Infections
More
Approved
Login to view more data

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Profit

Explore the financial positions of over 360K organizations with Synapse.
login
or
view full example data
Explore the financial positions of over 360K organizations with Synapse.

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.
login
or
view full example data
Access more than 2 million grant and funding information to elevate your research journey.

Investment

Gain insights on the latest company investments from start-ups to established corporations.
login
or
view full example data
Gain insights on the latest company investments from start-ups to established corporations.

Financing

Unearth financing trends to validate and advance investment opportunities.
login
or
view full example data
Unearth financing trends to validate and advance investment opportunities.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free